Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women

NCT05042362 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05042362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05042362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2021
Completion date
November 27, 2023
Enrollment
396 (actual)
Sites
99

Conditions

As the registry lists them; a condition with its own page is linked.

hot flashes, vasomotor symptoms associated with menopause